The present study aimed at investigating the prevalence of factor V Leiden G1691A, prothrombin G20210A, and MTHFR C677T in cerebral venous and sinus thrombosis (CVST) patients and their possible association with CVST in Western Iran. A total of 24 CVST patients with the mean age of 37.1 + 11.7 years and 100 sex-and age-matched healthy individuals from Kermanshah Province of Iran with ethnic background of Kurd were studied for factor V Leiden G1691A, prothrombin G20210A and MTHFR C677T by PCR-RFLP method using Mnl I, Hind III, and Hinf I restriction enzymes, respectively. Prevalence of factor V Leiden was 16.7% in patients and 2% in control group. A significant association was found between factor V Leiden mutation and CVST with odds ratio (OR) of 9.8 (95% confidence intervals [CI] 1.68-57.2, P ¼ .01). No prothrombin G20210A was found among patients. In patients, MTHFR C677T tended to be higher (58.3%) compared to control (44%), OR of 1.8 (95% CI 0.73-4.5, P ¼ .2). Our study for the first time has determined the prevalence of inherited thrombophilia in a homogenous ethnic group of CVST patients and suggests that factor V Leiden, and not the prothrombin gene mutation is a risk factor for CVST in Western Iran.
Introduction
The factor V (FV) Leiden polymorphism is caused by a single-point mutation at nt1691, leading to an Arg/ Gln amino acid exchange at position 506. This mutation occurs in approximately 5% of the Caucasian population and represents one of the most important risk factors for inherited thrombophilia. 1 A single nucleotide exchange (G!A transition) at position 20210 in the 3 0 -untranslated region of the prothrombin gene in patients with a family history of venous thrombosis has been described by Poort et al. 2 The presence of this mutation is associated with an approximately 25% increase in plasma thrombin activity.
Cerebral venous and sinus thrombosis (CVST) is an uncommon condition that often affects young to middle-aged patients and more commonly women. 1 The superior sagital and lateral sinuses are commonly (70%) individually involved by thrombosis. In 30%, both are affected, in addition to cortical and cerebral veins. 3 Three highly prevalent mutations have been described in association with thrombosis; factor V Leiden, the prothrombin G20210A, and the homozygosity for the thermolabile methylene tetrahydrofolate reductase (MTHFR 677TT). 4 Cerebral venous and sinus thrombosis is a multifaceted disorder. It has multiple predisposing factors including pregnancy and postpartum state, surgery, head trauma, arterio-venous malformations, infections, paraneoplastic and autoimmune disease, and the use of oral contraceptives (OC). In addition, inherited blood coagulation disorders play an important role in the development of CVST. 5 Until now, there are few published reports about CVST associated with FV Leiden mutation as an isolated thrombophilic factor.
Recently, we established a prevalence of 2.97% for factor V Leiden mutation among normal population of Kermanshah. 6 Also we found that CVST is not rare among population of Kermanshah.
The aim of the current study was to determine the prevalence of FV Leiden, prothrombin G20210A, and MTHFR C677T among patients with CVST from Western Iran compared to healthy individuals to find the possible association between these mutations and CVST in Iran.
Materials and Methods
Between June 2007 and June 2008, 26 patients with CVST were referred to the neurology departments of 2 hospitals of Kermanshah University of Medical Sciences. Because the amount of DNA from 2 patients was not enough for doing experiments we were able to study 24 unrelated CVST patients. The patients group comprised 7 males (29.2%) and 17 (70.8%) females with the mean age of 37.1 + 11.7 years who were referred to the Imam Reza and Farabi Hospitals of Kermanshah University of Medical Sciences and diagnosed with CVST. The presence of CVST was confirmed by magnetic resonance imaging (MRI). In addition, 100 age-and sex-matched healthy individuals including 50 males and 50 females, with the mean age of 36.1 + 13.3 years, were studied as a control group. The healthy individuals were staff members of the medical faculty of Kermanshah University and blood donors without history of CVST from the same area.
All studied individuals were from the Kermanshah Province of Iran, with ethnic background of Kurd. Informed written consent was obtained from each individual before participation. The study was approved by the Ethics Committee of Kermanshah University of Medical Sciences and was in accordance with the principles of the Declaration of Helsinki II.
DNA was extracted by phenol chloroform method. 7 The G1691A mutation was identified by the amplification of a 267-base pairs (bp) fragment in exon 10 of the factor V and subsequent digestion with Mnl I restriction enzyme as described by Bertina et al. 8 To detect prothrombin G20210A a 345-bp fragment from exon 14 and 3 0 -untranslated region of prothrombin gene was amplified and digested with Hind III restriction enzyme according to Poort et al 2 method. To identify the MTHFR C677T, a 198-bp region in exon 4 of gene was amplified and polymerase chain reaction (PCR)amplified products were treated with Hinf I restriction endonuclease. 9
Statistical Analysis
Allele frequencies were calculated by the genecounting method. The genotypes and allele frequencies of factor V Leiden, prothrombin G20210A, and MTHFR C677T in patients were compared to control using the chi-square analysis. Two tailed student t test was used to compare quantitative data. The age and sex were matched in 2 groups of patients and controls. Odds ratios (OR) and their 95% confidence intervals (CI) were calculated using logistic regression to estimate the relative risk of disease. In logistic regression analysis we selected CVST as a dependent variable that was designated with code 1 and the absence of CVST was introduced as code 0. Independent variable was mutation in each genetic factor compared to wild genotype. When both homozygous and heterozygous genotypes existed both of them were considered as an independent variable that was compared to dependent variable of CVST. The statistical significance was assumed at the P < .05 level. The SPSS software package version 12 was used for statistical analysis.
Results
The characteristics of patients and controls are demonstrated in Table 1 . The prevalence and allele frequencies of FV Leiden, prothrombin G20210A, and MTHFR C677T among CVST patients and control group are shown in Table 1 . In 53.8% and 7.7% of patients the lateral and sigmoid sinuses were involved by thrombosis, respectively. In 38.5% of patients, both were affected.
Prothrombin G20210A mutation was not found in patients. However, 1 person out of 100 (1%) healthy individuals was a carrier of this mutation. A significantly high prevalence of FV Leiden was found in CVST patients from Western Iran compared to normal individuals. Factor V Leiden mutation was detected in 4 out of 24 CVST patients (16.7%), 2 males and 2 females, and in 2% of control group (P ¼ .01).
Adjusted logistic regression analysis for the effects of age and sex was performed and a significant association was found between FV Leiden mutation and CVST with OR of 9.8 (95% confidence intervals [CI] 1.68-57.2, P ¼ .01). None of the CVST patients were homozygous for FV Leiden mutation. The frequency of FV Leiden mutation in patients and its association with CVST are indicated in Table 1 .
Heterozygous MTHFR C677T was found in 12 (50%) CVST patients and homozygous MTHFR 677TT was found in 2 patients (8.3%) giving an overall prevalence of 58.3% for this mutation among patients. MTHFR C677T polymorphism was detected as heterozygous in 40 (40%) healthy participants and as homozygous in 4 individuals (4%). The overall prevalence of MTHFR C677T in healthy individuals was (44%). No significant difference was found between patient group and control related to the prevalence of MTHFR C677T, OR of 1.82 (95% confidence intervals [CI] 0.73-4.5, P ¼ .2).
One of our CVST patients combined heterozygous for FV Leiden and MTHFR C677T died during hospitalization.
Studying acquired risk factors indicated that 7 out of 17 women with CVST (41.2%) were OC users. None of OC-user women had inherited thrombophilia. Also, among patients there were 1 woman with hypertension and hypertriglyceridemia (heterozygous for MTHFR C677T), 1 woman with hypothyroidism and history of abortion, 1 woman with diabetes, and 1 man with gout (heterozygous for MTHFR C677T). Thrombophilic mutations of FV Leiden and prothrombin G20210A were not detected in these patients.
Discussion
The current study has identified a high prevalence of FV Leiden among Iranian CVST patients with Kurdish ethnic background compared to healthy individuals and detected an association between this mutation and CVST. The prevalence of thrombophilic mutations in CVST patients has been addressed in few studies.
Inherited gene disorders related to the hemostatic system have been documented as risk factors for thrombosis. The mutation in FV Leiden G1691A and the prothrombin gene G20210A are the 2 most prevalent known causes of inherited thrombophilia. 10 There are few studies investigating the association between thrombophilic mutations with inherited thrombophilia. The frequency of FV 1691A in patients with cerebral venous thrombosis (CVT) varied from 3.7% to 25%. 11 The frequency of prothrombin 20210A was found to be from 0% to 20%. 11 MTHFR 677TT frequency was reported from 0% to 36%. 11 Ludemann et al 12 found the presence of heterozygous FV Leiden mutation in 14.5% of patients with CVT but in only 6.25% of controls (OR 2.55). They confirmed that FV Leiden mutation is the most relevant hereditary risk factor for CVT and patients with this mutation are at an increased risk for recurrent venous thrombosis.
Also, Lichy et al 13 reported that among patients with CVT from Southern Germany, the prevalence of FV Leiden tended to be higher (OR 2.08, 95% CI 0.91-4.75, P ¼ .06). However, the prevalence of prothrombin 20210A was significantly higher in patients with CVT than in controls (OR 4.57, 95% CI 1.45-14.44, P ¼ .007). The presence of prothrombin 20210A in this population increased risk of CVT 4.5-fold. In 16 Lebanese patients with CVST, the FV Leiden mutation was found to be the most common inherited risk factor for CVST, which was presented in 31.2% of patients. 5 Finally, recent However, in the study of Buyru, 15 no evidence of an association between FV Leiden mutation and a risk of cerebrovascular disease was found.
Our results indicate that the inherited FV Leiden is an important risk factor for CVST with a prevalence of 16.7% in CVST patients and increased the risk of CVST up to 9.8 times. We found heterozygosity for FV Leiden and no homozygous FV Leiden was found in patients. Presumably, the absence of homozygotes can be explained by the lower frequency of homozygotes in the population.
We did not find prothrombin G20210A mutation among our patients, which demonstrates this mutation is not an important risk factor for CVST in our population. There are few studies from various populations indicating that prothrombin mutation and not FV Leiden is the most important risk factor for CVST. The study of Gadelha et al 11 indicated a high prevalence of inherited thrombophilia in patients with CVT. Prothrombin 20210A was the most frequent hereditary disorder in their patients, showing the strongest association with CVT. In their study, FV1691A, after matching by gender, was associated with CVT. Dentali et al 14 found 9 studies investigating the role of prothrombin mutation in CVT, for a total of 360 patients and 2688 controls. The pooled OR for CVT was 9.27 (95% CI, 5.85-14.67; P < .001) in patients with prothrombin mutation compared to controls. Rodrigues et al 16 investigated the prevalence of prothrombin mutation in 42 consecutive patients with CVT and compared them with 134 healthy participants and found this mutation in 16.7% of patients and 0.7% of the control group, yielding an OR for CVT of 26.6 (95% CI, 3.2-223.5). They concluded that in Brazilian population prothrombin G20210A mutation and OC use are significant risk factors for CVT, whereas FV Leiden mutation does not show significant association with CVT. 16 MTHFR C677T has been a candidate genetic risk factor for venous thrombosis because its phenotype, elevated serum homocysteine level, is associated with venous thrombosis. 17 MTHFR 677T may cause moderate hyperhomocysteinaemia in the presence of vitamin deficiencies (folates, B6 or B12) that may be too small to cause thrombosis on its own. 4, 11, 17 In the Leiden Thrombophilia Study, 18 the risk of thrombosis was only increased when homocysteine concentrations were above 2.43 mg/L (>18 mmol/L), compared with a reference level below 1.62 mg/L (<12 mmol/L), which corresponds to at least 50% higher homocysteine concentrations. The 25% increase in homocysteine concentrations that is generally observed in individuals with the MTHFR 677TT genotype may therefore not be enough in most cases to cause thrombosis. Further, in a recent study of Turkish patients with thromboembolism, total plasma level of homocystein in patient and control groups were similar. 19 MTHFR 677TT has not settled as a strong risk factor for CVST yet. 4 In a very large population-based case-control study, MTHFR C677T was not associated with the risk of venous thrombosis. 17 However, in our patients, MTHFR C677T tended to be higher (58.3%) compared to control (44%), OR of 1.8 (95% confidence intervals [CI] 0.73-4.5, P ¼ .2).
Oral contraceptive pill was found to be the most prevalent predisposing factor for CVST among studied women from the Isfahan Province of Iran, which was used by 38.1% of affected women for a period of as short as 1 to 3 months. 20 Our findings confirm a higher frequency of CVST in women (around 71%) than in men, mostly during reproductive age when there is an excessive exposure to exogenous (OC) and endogenous (pregnancy-related) sex hormones. The presence of about 41% of OC-user women with CVST and without inherited thrombophila indicates that OC might play an important role in CVST, but all inherited thrombophilia were not investigated in this study.
Janghorbani et al 21 in a clinic-based prospective case register study from Isfahan in central Iran estimated an annual frequency of 12.3 per million for CVST. The annual frequency of CVST was higher in women (19.9) than in men (5.1). Finding 26 cases with CVST in 2 hospitals of Kermanshah University of Medical Sciences during 1 year shows CVST might not be unusual in the Kermanshah Province of Iran and this severe venous thrombosis need more attention in our population.
In summary, our study for the first time has determined the prevalence of inherited thrombophilia in a homogenous ethnic group of CVST patients and suggests that FV Leiden, and not the prothrombin gene mutation, is a risk factor for CVST in Western Iran.
We studied all CVST patients who were referred to the 2 hospitals of Kermanshah University during 1 year. Because of the small sample size, a wide confidence interval was obtained, which could be a limitation of our study. Further investigations on genetic risk factors in CVST patients with larger number of individuals will be helpful to support our findings.
